$CVV
CVD EQUIPMENT CORP

2024 Q4 Form 10-Q Financial Statement

#000149315224045104 Filed on November 13, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3
Revenue $8.194M
YoY Change 31.44%
Cost Of Revenue $6.359M
YoY Change 37.17%
Gross Profit $1.835M
YoY Change 14.83%
Gross Profit Margin 22.39%
Selling, General & Admin $1.739M
YoY Change -7.7%
% of Gross Profit 94.77%
Research & Development $644.0K
YoY Change -8.52%
% of Gross Profit 35.1%
Depreciation & Amortization $169.0K
YoY Change 5.62%
% of Gross Profit 9.21%
Operating Expenses $1.758M
YoY Change -32.07%
Operating Profit $77.00K
YoY Change -107.78%
Interest Expense $131.0K
YoY Change 2083.33%
% of Operating Profit 170.13%
Other Income/Expense, Net $131.0K
YoY Change -44.73%
Pretax Income $208.0K
YoY Change -127.62%
Income Tax $5.000K
% Of Pretax Income 2.4%
Net Earnings $203.0K
YoY Change -126.96%
Net Earnings / Revenue 2.48%
Basic Earnings Per Share $0.03
Diluted Earnings Per Share $0.03
COMMON SHARES
Basic Shares Outstanding 6.882M shares 6.882M shares
Diluted Shares Outstanding 6.835M shares

Balance Sheet

Concept 2024 Q4 2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $10.01M
YoY Change -29.99%
Cash & Equivalents $10.00M
Short-Term Investments
Other Short-Term Assets $892.0K
YoY Change 5.19%
Inventory $2.558M
Prepaid Expenses
Receivables $5.124M
Other Receivables $0.00
Total Short-Term Assets $19.93M
YoY Change -19.98%
LONG-TERM ASSETS
Property, Plant & Equipment $11.91M
YoY Change -2.44%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $10.00K
YoY Change 0.0%
Total Long-Term Assets $11.92M
YoY Change -3.29%
TOTAL ASSETS
Total Short-Term Assets $19.93M
Total Long-Term Assets $11.92M
Total Assets $31.85M
YoY Change -14.45%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.393M
YoY Change -5.69%
Accrued Expenses $1.903M
YoY Change 11.22%
Deferred Revenue $3.288M
YoY Change -32.32%
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due $85.00K
YoY Change 6.25%
Total Short-Term Liabilities $6.669M
YoY Change -23.55%
LONG-TERM LIABILITIES
Long-Term Debt $203.0K
YoY Change -29.51%
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $203.0K
YoY Change -29.51%
TOTAL LIABILITIES
Total Short-Term Liabilities $6.669M
Total Long-Term Liabilities $203.0K
Total Liabilities $6.872M
YoY Change -23.74%
SHAREHOLDERS EQUITY
Retained Earnings -$4.590M
YoY Change 1504.9%
Common Stock $29.56M
YoY Change 3.73%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $24.97M
YoY Change
Total Liabilities & Shareholders Equity $31.85M
YoY Change -14.45%

Cashflow Statement

Concept 2024 Q4 2024 Q3
OPERATING ACTIVITIES
Net Income $203.0K
YoY Change -126.96%
Depreciation, Depletion And Amortization $169.0K
YoY Change 5.62%
Cash From Operating Activities $32.00K
YoY Change -95.73%
INVESTING ACTIVITIES
Capital Expenditures $37.00K
YoY Change -53.75%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$37.00K
YoY Change -107.12%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -21.00K
YoY Change 5.0%
NET CHANGE
Cash From Operating Activities 32.00K
Cash From Investing Activities -37.00K
Cash From Financing Activities -21.00K
Net Change In Cash -26.00K
YoY Change -102.08%
FREE CASH FLOW
Cash From Operating Activities $32.00K
Capital Expenditures $37.00K
Free Cash Flow -$5.000K
YoY Change -100.75%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q3 us-gaap Gain Loss On Sale Of Business
GainLossOnSaleOfBusiness
usd
CY2024Q3 us-gaap Asset Impairment Charges
AssetImpairmentCharges
usd
CY2023Q3 us-gaap Asset Impairment Charges
AssetImpairmentCharges
usd
CY2024Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
usd
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
dei Entity Central Index Key
EntityCentralIndexKey
0000766792
CY2024Q3 us-gaap Gain Loss On Sale Of Business
GainLossOnSaleOfBusiness
usd
dei Document Type
DocumentType
10-Q
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
10005000 usd
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
14025000 usd
CY2024Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
5124000 usd
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1906000 usd
CY2024Q3 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
1348000 usd
CY2023Q4 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
1604000 usd
CY2024Q3 us-gaap Inventory Net
InventoryNet
2558000 usd
CY2023Q4 us-gaap Inventory Net
InventoryNet
4454000 usd
CY2024Q3 us-gaap Other Assets Current
OtherAssetsCurrent
892000 usd
CY2023Q4 us-gaap Other Assets Current
OtherAssetsCurrent
852000 usd
CY2024Q3 us-gaap Assets Current
AssetsCurrent
19927000 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
22841000 usd
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
11909000 usd
CY2024Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
10000 usd
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
18000 usd
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
6669000 usd
CY2024Q3 us-gaap Liabilities
Liabilities
6872000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
19998000 usd
CY2023Q3 us-gaap Cost Of Revenue
CostOfRevenue
4636000 usd
us-gaap Cost Of Revenue
CostOfRevenue
15158000 usd
CY2024Q3 us-gaap Gross Profit
GrossProfit
1835000 usd
CY2024Q3 us-gaap Assets
Assets
31846000 usd
CY2024Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
1393000 usd
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1903000 usd
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1765000 usd
CY2024Q3 us-gaap Long Term Debt Current
LongTermDebtCurrent
85000 usd
CY2023Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
81000 usd
CY2024Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
203000 usd
CY2023Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
268000 usd
CY2023Q4 us-gaap Liabilities
Liabilities
8822000 usd
CY2023Q4 CVV Deposits From Purchaser Of Mesoscribe Assets
DepositsFromPurchaserOfMesoscribeAssets
597000 usd
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
68000 usd
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
28695000 usd
CY2023Q4 us-gaap Assets
Assets
35025000 usd
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1203000 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
8554000 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-2560000 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
26203000 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
35025000 usd
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
6234000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
19462000 usd
us-gaap Cost Of Revenue
CostOfRevenue
14579000 usd
us-gaap Gross Profit
GrossProfit
4304000 usd
us-gaap Gross Profit
GrossProfit
5419000 usd
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
704000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1865000 usd
CY2023Q3 us-gaap Selling Expense
SellingExpense
434000 usd
us-gaap Selling Expense
SellingExpense
1268000 usd
us-gaap Selling Expense
SellingExpense
1281000 usd
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1450000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4057000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4410000 usd
CY2023Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
4908000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2055000 usd
CY2024Q3 CVV Deposits From Purchaser Of Mesoscribe Assets
DepositsFromPurchaserOfMesoscribeAssets
usd
CY2023Q3 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
usd
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
usd
us-gaap Gain Loss On Sale Of Business
GainLossOnSaleOfBusiness
usd
us-gaap Asset Impairment Charges
AssetImpairmentCharges
usd
CY2023Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
usd
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
usd
CY2024Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
usd
CY2023Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
usd
us-gaap Gain Loss On Sale Of Business
GainLossOnSaleOfBusiness
usd
us-gaap Asset Impairment Charges
AssetImpairmentCharges
usd
CVV Increase Decrease In Employee Retention Credit Receivable
IncreaseDecreaseInEmployeeRetentionCreditReceivable
usd
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
usd
CVV Proceeds From Deposits From Purchaser Of Mesoscribe Assets
ProceedsFromDepositsFromPurchaserOfMesoscribeAssets
usd
us-gaap Cash Divested From Deconsolidation
CashDivestedFromDeconsolidation
usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
usd
CY2023Q3 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
shares
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
shares
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
shares
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
1-16525
dei Entity Registrant Name
EntityRegistrantName
CVD EQUIPMENT CORPORATION
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NY
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
11-2621692
dei Entity Address Address Line1
EntityAddressAddressLine1
355 South Technology Drive
dei Entity Address City Or Town
EntityAddressCityOrTown
Central Islip
dei Entity Address State Or Province
EntityAddressStateOrProvince
NY
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
11722
dei City Area Code
CityAreaCode
(631)
dei Local Phone Number
LocalPhoneNumber
981-7081
dei Security12b Title
Security12bTitle
Common Stock
dei Trading Symbol
TradingSymbol
CVV
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
6881838 shares
dei Entity Listing Par Value Per Share
EntityListingParValuePerShare
0.01
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
12166000 usd
CY2024Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
3288000 usd
CY2023Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
4908000 usd
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
20000000 shares
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
20000000 shares
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
6881838 shares
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
6881838 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
6824511 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
6824511 shares
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
69000 usd
CY2024Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
29495000 usd
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-4590000 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
24974000 usd
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
31846000 usd
CY2024Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
8194000 usd
CY2024Q3 us-gaap Cost Of Revenue
CostOfRevenue
6359000 usd
CY2023Q3 us-gaap Gross Profit
GrossProfit
1598000 usd
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
644000 usd
CY2024Q3 us-gaap Selling Expense
SellingExpense
423000 usd
CY2024Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1316000 usd
CY2024Q3 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
625000 usd
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
625000 usd
us-gaap Gain Loss On Sale Of Business
GainLossOnSaleOfBusiness
-162000 usd
us-gaap Asset Impairment Charges
AssetImpairmentCharges
111000 usd
CY2024Q3 us-gaap Operating Expenses
OperatingExpenses
1758000 usd
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
2588000 usd
us-gaap Operating Expenses
OperatingExpenses
6755000 usd
us-gaap Operating Expenses
OperatingExpenses
7829000 usd
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
77000 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-990000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-2451000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-2410000 usd
CY2024Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
136000 usd
CY2023Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
173000 usd
us-gaap Investment Income Interest
InvestmentIncomeInterest
438000 usd
us-gaap Investment Income Interest
InvestmentIncomeInterest
400000 usd
CY2024Q3 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
5000 usd
CY2023Q3 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
6000 usd
us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
14000 usd
us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
18000 usd
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
42000 usd
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
70000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
91000 usd
CY2024Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
131000 usd
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
237000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
426000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
515000 usd
CY2024Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
208000 usd
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-753000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-2025000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-1895000 usd
CY2024Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
5000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
5000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
11000 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
203000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-753000 usd
us-gaap Net Income Loss
NetIncomeLoss
-2030000 usd
us-gaap Net Income Loss
NetIncomeLoss
-1906000 usd
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.03
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.11
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.30
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.28
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.03
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.11
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.30
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.28
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
6825495 shares
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
6789487 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
6817220 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
6787415 shares
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
6834627 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
6789487 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
6817220 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
6787415 shares
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
24504000 usd
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
203000 usd
CY2024Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
267000 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
24974000 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
28719000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-753000 usd
CY2023Q3 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
250000 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
28216000 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
26203000 usd
us-gaap Net Income Loss
NetIncomeLoss
-2030000 usd
us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
801000 usd
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
24974000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
29399000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
29399000 usd
us-gaap Net Income Loss
NetIncomeLoss
-1906000 usd
us-gaap Net Income Loss
NetIncomeLoss
-1906000 usd
us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
647000 usd
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
76000 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
28216000 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
28216000 usd
us-gaap Net Income Loss
NetIncomeLoss
-2030000 usd
us-gaap Net Income Loss
NetIncomeLoss
-1906000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
801000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
647000 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
476000 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
545000 usd
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
625000 usd
us-gaap Gain Loss On Sale Of Business
GainLossOnSaleOfBusiness
-162000 usd
us-gaap Inventory Write Down
InventoryWriteDown
1253000 usd
us-gaap Inventory Write Down
InventoryWriteDown
197000 usd
us-gaap Asset Impairment Charges
AssetImpairmentCharges
111000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
3218000 usd
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-1163000 usd
us-gaap Increase Decrease In Contract With Customer Asset
IncreaseDecreaseInContractWithCustomerAsset
-256000 usd
us-gaap Increase Decrease In Contract With Customer Asset
IncreaseDecreaseInContractWithCustomerAsset
725000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-633000 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
1953000 usd
CVV Increase Decrease In Employee Retention Credit Receivable
IncreaseDecreaseInEmployeeRetentionCreditReceivable
-1529000 usd
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-48000 usd
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
46000 usd
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-8000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
140000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
113000 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
138000 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-729000 usd
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-1620000 usd
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
816000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3740000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-76000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
219000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
308000 usd
CVV Proceeds From Deposits From Purchaser Of Mesoscribe Assets
ProceedsFromDepositsFromPurchaserOfMesoscribeAssets
597000 usd
us-gaap Cash Divested From Deconsolidation
CashDivestedFromDeconsolidation
312000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-219000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-23000 usd
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
61000 usd
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
57000 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
76000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-61000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
19000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-4020000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-80000 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
14025000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
14365000 usd
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
10005000 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
14285000 usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
2000 usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
11000 usd
us-gaap Interest Paid Net
InterestPaidNet
14000 usd
us-gaap Interest Paid Net
InterestPaidNet
18000 usd
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
10000000.0 usd
CY2024Q3 us-gaap Capitalized Contract Cost Impairment Loss
CapitalizedContractCostImpairmentLoss
0 usd
us-gaap Capitalized Contract Cost Impairment Loss
CapitalizedContractCostImpairmentLoss
0 usd
CY2023Q3 us-gaap Capitalized Contract Cost Impairment Loss
CapitalizedContractCostImpairmentLoss
0 usd
us-gaap Capitalized Contract Cost Impairment Loss
CapitalizedContractCostImpairmentLoss
0 usd
CY2023Q2 us-gaap Deferred Revenue
DeferredRevenue
800000 usd
us-gaap Standard Product Warranty Description
StandardProductWarrantyDescription
The Company typically provides standard warranty coverage on its systems for one year from the date of final acceptance or fifteen months from the date of shipment by providing labor and parts necessary to repair the systems during the warranty period.
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
10000000.0 usd
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
14000000.0 usd
CY2024Q3 us-gaap Cash Uninsured Amount
CashUninsuredAmount
0 usd
CY2023Q4 us-gaap Cash Uninsured Amount
CashUninsuredAmount
1500000 usd
CY2024Q3 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
36000 usd
CY2023Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
36000 usd
CY2024Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
8194000 usd
CY2023Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
6234000 usd
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
19462000 usd
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
19998000 usd
CY2024Q3 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
17000000.0 usd
CY2024Q3 CVV Costs Incurred On Uncompleted Contracts
CostsIncurredOnUncompletedContracts
13540000 usd
CY2024Q3 CVV Estimated Earnings
EstimatedEarnings
6672000 usd
CY2024Q3 CVV Costs And Estimated Earnings On Uncompleted Contracts
CostsAndEstimatedEarningsOnUncompletedContracts
20212000 usd
CY2024Q3 CVV Billings To Date
BillingsToDate
21693000 usd
CY2024Q3 CVV Net Cost In Excess Of Billings
NetCostInExcessOfBillings
-1481000 usd
CY2024Q3 CVV Deferred Revenues Related To Contracts
DeferredRevenuesRelatedToContracts
459000 usd
CY2024Q3 CVV Contract Liability In Excess Of Contract Assets
ContractLiabilityInExcessOfContractAssets
1940000 usd
CY2024Q3 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
1348000 usd
CY2024Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
3288000 usd
CY2023Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
4600000 usd
CY2022Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
4000000.0 usd
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
4200000 usd
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
3700000 usd
CY2024Q3 us-gaap Inventory Raw Materials
InventoryRawMaterials
1366000 usd
CY2023Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
2351000 usd
CY2024Q3 us-gaap Inventory Work In Process
InventoryWorkInProcess
661000 usd
CY2023Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
1248000 usd
CY2024Q3 us-gaap Inventory Finished Goods
InventoryFinishedGoods
531000 usd
CY2023Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
855000 usd
CY2024Q3 us-gaap Inventory Net
InventoryNet
2558000 usd
CY2023Q4 us-gaap Inventory Net
InventoryNet
4454000 usd
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
6825495 shares
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
6789487 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
6817220 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
6787415 shares
CY2024Q3 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
9132 shares
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
6834627 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
6789487 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
6817220 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
6787415 shares
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
838125 shares
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
493750 shares
CY2024Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
267000 usd
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
249000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
801000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
647000 usd
CY2024Q3 us-gaap Share Price
SharePrice
4.75
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
4.75
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.77 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0412 pure
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
846875 shares
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
8.20
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
5000 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
4.75
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
13750 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
7.94
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
838125 shares
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
8.18
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
3 segment
CY2024Q3 us-gaap Assets
Assets
31846000 usd
CY2024Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
8194000 usd
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
77000 usd
CY2024Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
208000 usd
CY2024Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
169000 usd
CY2024Q3 us-gaap Segment Expenditure Addition To Long Lived Assets
SegmentExpenditureAdditionToLongLivedAssets
37000 usd
CY2023Q3 us-gaap Assets
Assets
37227000 usd
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
6234000 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-990000 usd
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-753000 usd
CY2023Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
153000 usd
CY2023Q3 us-gaap Segment Expenditure Addition To Long Lived Assets
SegmentExpenditureAdditionToLongLivedAssets
83000 usd
CY2024Q3 us-gaap Other Noncash Expense
OtherNoncashExpense
1000000.0 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
19462000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-2451000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-2025000 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
476000 usd
us-gaap Segment Expenditure Addition To Long Lived Assets
SegmentExpenditureAdditionToLongLivedAssets
219000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
19998000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-2410000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-1895000 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
545000 usd
us-gaap Segment Expenditure Addition To Long Lived Assets
SegmentExpenditureAdditionToLongLivedAssets
308000 usd
us-gaap Other Noncash Expense
OtherNoncashExpense
1000000.0 usd

Files In Submission

Name View Source Status
0001493152-24-045104-index-headers.html Edgar Link pending
0001493152-24-045104-index.html Edgar Link pending
0001493152-24-045104.txt Edgar Link pending
0001493152-24-045104-xbrl.zip Edgar Link pending
cvv-20240930.xsd Edgar Link pending
ex31-1.htm Edgar Link pending
ex31-2.htm Edgar Link pending
ex32-1.htm Edgar Link pending
ex32-2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
form10-q.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
cvv-20240930_def.xml Edgar Link unprocessable
cvv-20240930_lab.xml Edgar Link unprocessable
cvv-20240930_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
form10-q_htm.xml Edgar Link completed
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
cvv-20240930_cal.xml Edgar Link unprocessable